MiMedx Group/$MDXG
MiMedx shares fall after Q2 results showed net sales down 35% yoy, adjusted EBITDA of negative $8M, and unveiled a $300M term loan at SOFR+6.25% to finance its $35-per-share Sanara MedTech acquisition.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Ticker
$MDXG
Sector
Primary listing
Employees
808
Headquarters
Website
MiMedx Group Metrics
BasicAdvanced
$636m
21.24
$0.20
1.65
-
Price and volume
Market cap
$636m
Beta
1.65
52-week high
$7.99
52-week low
$3.03
Average daily volume
1.4m
Financial strength
Current ratio
5.395
Quick ratio
4.62
Long term debt to equity
6.625
Total debt to equity
7.242
Interest coverage (TTM)
23.19%
Profitability
EBITDA (TTM)
52.882
Gross margin (TTM)
81.04%
Net profit margin (TTM)
7.88%
Operating margin (TTM)
10.17%
Effective tax rate (TTM)
27.47%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
8.54%
Return on equity (TTM)
13.77%
Valuation
Price to earnings (TTM)
21.241
Price to revenue (TTM)
1.624
Price to book
2.62
Price to tangible book (TTM)
3.02
Price to free cash flow (TTM)
9.123
Free cash flow yield (TTM)
10.96%
Free cash flow per share (TTM)
0.468
Growth
Revenue change (TTM)
10.51%
Earnings per share change (TTM)
-25.95%
3-year revenue growth (CAGR)
11.54%
10-year revenue growth (CAGR)
6.90%
3-year earnings per share growth (CAGR)
-10.20%
10-year earnings per share growth (CAGR)
-1.37%
What the Analysts think about MiMedx Group
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
MiMedx Group Financial Performance
Revenues and expenses
MiMedx Group Earnings Performance
Company profitability
MiMedx Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.